Browse our latest Cancer Biology articles

The stanniocalcin-1-dependent immunosuppressive roles of mesenchymal stem cell on chimeric antigen receptor modified T cell therapy.

eRNAs detected in patient-derived transcriptomic data can delineate potential active enhancer regions in oesophageal adenocarcinoma and uncover genes associated with the cancer phenotype.

Cancer invasion occurs with different molecular and spatial patterns, thin invading strands are associated with mesenchymal cell features, such as low cell-cell adhesion, while broad strands are favoured for lymph node metastasis and require high matrix proteolysis and cell-cell adhesions.

The fatty acid binding protein (FABP) family of proteins plays a role in multiple myeloma cell survival and disease progression in vitro and in silico, and thus blocking the FABPs could have anti-cancer effects and prove beneficial for myeloma patients.

Identification of a pro-tumorigenic and pro-metastatic role of EHD2 protein in triple-negative breast cancer (TNBC) through the store-operated calcium entry (SOCE) pathway provides a rationale for potential targeting of EHD2-overexpressing TNBC with SOCE inhibitors.

Remdesivir is a promising treatment modality to reduce 30 day all-cause mortality.

Long COVID occurred in the majority of cancer patients diagnosed with acute COVID-19 with a preponderance of symptoms (such as fatigue, sleep disturbances, and gastrointestinal symptoms) over a long time period.

Multi-omic profiling of tumor-infiltrating T cells provides new insights into the differences in the effectiveness of CDK4 inhibitor between human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinoma patients.

As macrophages are involved in various aspects of non-small cell lung cancer development and progression it is crucial to develop appropriate 3D co-culture platforms for modeling immune cell-tumor cell interactions, leading to more efficacious macrophage-focused immunotherapies.

Protein kinase A-driven increases in c-MYC protein expression and tumor cell proliferation can be blocked by eIF4A inhibitors, suggesting a potential new treatment option for patients with oncogenic PKA activation.